Endpoints News

Mirador reveals its first program		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

17 July, 2026

The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.

news

GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyout

Mirador unveils a piece of pipeline with drug from Kira to rival troubled Tavneos

Peer Review

Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire

Q&A: Betty Tijms says it’s time to stop treating Alzheimer’s as a single disease

Jul 30

1:00 pm ET

Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights

sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology

Terray Therapeutics, Inc.

Monrovia, CA, USA

Senior Director, Licensing Officer

Bayer

Cambridge, MA, USA

Recruit talent with Endpoints Careers

Contact Meg Estacio: mestacio@endpointsnews.com

A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.

in case you missed it

US drug shortages rise for third straight quarter, hurt by lone suppliers

Updated: Sanofi, Arbutus file separate suits against mRNA vaccine makers over LNP tech patents

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

Updated: Merck beats AstraZeneca to approval for first PCSK9 pill

News Briefing

Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer's Hernexeos

‘Explosive diarrhoea’ outbreak grips US: how researchers are hunting its source

For families facing a deadly brain cancer, scientific progress can’t come soon enough

Acquisitions are always a bit of a gamble. Losing its stake today is GSK, which has dropped the cough candidate that was the centerpiece of its $2 billion purchase of Bellus Health in 2023. Ayisha Sharma has the lowdown on the trial miss that led GSK to give up on the disease.

Elizabeth Cairns

Senior Biopharma Journalist, Endpoints News